Severe combined immunodeficiency (SCID) [20 genes]

Severe combined immunodeficiency (SCID) represents a group of rare, and potentially lethal, primary immunodeficiencies (PIDs) characterized by the lack of functional peripheral T cells, which are classified as SCID (T-B+) or SCID (T-B-) based on the presence or absence of functional B cells >, respectively.
In both cases, these defects may be accompanied by absence of functional NK cells. SCDI is caused by alterations in different genes involved in the maturation and function of the T-cell, B-cell, and NK-cell lineage.

  • 1-9/1,000,000
  • 40-100 newborns/year in USA

  • Differential diagnosis with BLS or agammaglobulinemia
  • Genetic counseling
  • Hematopoietic stem cell transplantation (HSCT)
  • Gene therapy

Identifying a genetic defect responsible for the disease would allow a precise molecular diagnosis to be issued and make it possible to provide genetic counseling to the patient and their family members. In some cases, detecting a genetic variant can help explore specific treatment options.

In the case of severe combined immunodeficiencies, the treatment is usually bone marrow transplantation, but new emerging gene therapies open the door to other treatments that may be applied shortly.

  • Severe life-threatening infections (viral, fungal, bacterial)
  • Diarrhea
  • Failure to thrive
  • Autoimmunity
  • Onset: neonatal, infancy

Request study Informed consent
Steps to follow
Steps to follow

How to order

1. Download & fill out

Please cover as many fields as possible in both documents

2. Sample collection

Three sample types: saliva, peripheral blood or genomic DNA

3. Pack the sample

Please pack the sample in a way to prevent leakage

4. Send the sample & the request

Please schedule the delivery for Monday–Friday: 8am – 5pm

5. Result: the report

Via: e-mail and/or through the customer portal

Ask for information
Solicita información de

Severe combined immunodeficiency (SCID)

"*" indicates required fields

Consentimiento*
This field is for validation purposes and should be left unchanged.
Technique: NGS capture panel

Turnaround time (TAT): 25 days

Ref. S-202110433

Severe combined immunodeficiency (SCID): View panel
  • ADA
  • AK2
  • CD247
  • CD3D
  • CD3E
  • CD3G
  • CORO1A
  • DCLRE1C
  • FOXN1
  • IL2RA
  • IL2RB
  • IL2RG
  • IL7R
  • JAK3
  • LIG4
  • NHEJ1
  • PRKDC
  • PTPRC
  • RAG1
  • RAG2

Priority Genes : Genes where there is sufficient evidence (clinical and functional) to consider them associated with the disease; they are included in the clinical practice guidelines.
Secondary Genes: Genes related to the disease, but with a lower level of evidence or that constitute sporadic cases.
* Candidate Genes: Not enough evidence in humans, but potentially associated with the disease.

References

  1. Bousfiha A, Jeddane L, Picard C, et al. The 2017 IUIS Phenotypic Classification for Inmunodeficiencias primarias. J Clin Immunol. 2018;38(1):129-143. doi:10.1007/s10875-017-0465-8
  2. Fischer, A. (2000). Severe combined immunodeficiencies (SCID). Clinical and Experimental Immunology, 122(2), 143–149. https://doi.org/10.1046/J.1365-2249.2000.01359.X
  3. Immune deficiency foundation (IDF). Severe Combined Immune Deficiency and Combined Immune Deficiency. https://primaryimmune.org/about-primaryimmunodeficiencies/specific-disease-types/severe-combined-immune-deficiency-and-combined-immune-deficiency. Accessed April 5, 2018.
  4. National Human Genome Research Institute (NHGRI). Learning About Severe Combined Immunodeficiency (SCID). https://www.genome.gov/13014325/learning-about-severe-combined-immunodeficiency-scid/. Published 2014. Accessed April 5, 2018.
  5. Rivers, L., & Gaspar, H. B. (2015). Severe combined immunodeficiency: recent developments and guidance on clinical management. Archives of Disease in Childhood, 100(7), 667–672. https://doi.org/10.1136/archdischild-2014-306425